PubMed Trending Research Digest — August 21, 2026
A curated digest of 94 trending PubMed articles, automatically categorised and summarised across 15 research areas.
Jump to category
PubMed Trending Research Digest — August 21, 2026
Automated digest · 94 articles · 15 research areas · August 21, 2026
Overview
Across this week’s set, a dominant theme is mechanistic precision—linking molecular circuitry to cell fate, disease progression, and therapeutic leverage. Several studies decode how regulatory programs are written and interpreted (e.g., transcription-factor “regulatory grammar” in developing neurons; epigenetic control of effector Tregs; immune-cell mitochondrial remodeling; and non-histaminergic mast cell–neuron signaling in chronic itch/pain). In parallel, multiple cancer and immune papers identify actionable nodes within complex systems: host factors for Brucella persistence, NET architecture control via RAD51, neutrophil-intrinsic Hippo/Vgll4 regulation of immunosuppressive switches, and tumor vulnerabilities driven by mitochondrial calcium–ferroptosis or PVT1-derived protein drivers.
A second major thread is translational strategy—turning mechanisms into interventions, diagnostics, or care pathways. Examples include engineered biologics and immune platforms (bispecific HA-targeting antibodies for H7 influenza; BCMA×CD3 affinity-biased T-cell engagers; base-edited “off-the-shelf” CAR T cells; and STING-controlled mRNA vaccine adjuvant design), as well as gene therapy/regeneration approaches (AAV ALPK3 replacement; iPSC cardiomyocyte feasibility; and bone/lymphatic and collateral-formation mechanistic targets). On the clinical side, the digest features multiple guideline and trial updates spanning liver disease (EASL/Baveno), MS diagnostic criteria, pediatric Crohn’s, SCLC standards, ITP treatment pathways, and multiple real-world or comparative-effectiveness studies (e.g., paclitaxel formulation, EV in renal impairment, tirzepatide vs semaglutide for liver outcomes, and post-PCI antithrombotic strategies).
Finally, the week highlights growing emphasis on system-level biomarkers and cross-system biology. Imaging and omics approaches are used to predict risk earlier than conventional measures (cortical thickness trajectories for Alzheimer’s amyloid conversion; cfDNA fragmentomics for high-risk pregnancy triage; and kidney-lupus nephritis single-cell atlases). Immunometabolic and microbiome-linked mechanisms also recur (gut cGAS–STING–IFN signaling in obesity; DNIC chemistry from nitrate+iron shaped by microbes; and gut flagellin–TLR5–IL-15–ARA axes converging across systemic inflammatory diseases). Together, these studies reflect a field moving toward integrated, multi-scale models—where cellular mechanisms, biomarkers, and pragmatic clinical workflows are increasingly designed to inform one another.
Neuronal development & gene regulation
TGW1a locus simultaneously shortens growth duration and boosts grain yield in rice.
This plant genetics study investigated the rice TGW1a locus (qTGW1a) and its flowering locus T-like gene TGW1a in rice to address the trade-off between growth duration and grain yield. The key finding is that TGW1a interacts with and stabilizes Ghd7 and Hd1 to improve nitrogen use efficiency and grain yield, and the promoter variant TGW1aJZ shortens growth duration by 3.67–8.67 days while increasing grain yield by 4.22–11.00% across multiple modern cultivars. Scientifically and agriculturally, it provides a genetic strategy to decouple heading time from yield components for higher annual rice productivity.
Li Z, Li G, Liu Z et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗
Myeloproliferative Neoplasms.
This review summarizes the molecular basis and clinical evolution of classic myeloproliferative neoplasms—essential thrombocythemia, polycythemia vera, and primary myelofibrosis—driven by gain-of-function mutations in JAK2, CALR, or MPL. It explains how early clonal hematopoiesis, shaped by comutations in epigenetic/splicing/signaling genes and amplified by inflammation, leads to disease progression and complications such as thrombosis and eventual transformation. The article frames current understanding of pathogenesis to guide risk assessment and therapeutic strategies targeting cytokine signaling and clonal evolution.
Plo I, Vainchenker W · The New England journal of medicine · (2026) · View on PubMed ↗
Regulatory logic of neuronal differentiation in the Drosophila visual system.
This study used simultaneous single-cell RNA-seq and ATAC-seq across four developmental stages of the Drosophila optic lobe to define how combinations of terminal selector transcription factors (tsTFs) specify neuronal enhancer programs in >250 cell types. The authors identified common cis-regulatory features of neuronal enhancers and perf [truncated], showing that tsTF combinations coordinate type-specific differentiation by shaping accessible chromatin and regulatory logic. These findings clarify the developmental “regulatory grammar” that links tsTF identity to neuronal fate and differentiation programs in vivo.
Treese M, Chen YC, Tyree A et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Neuroimmunology & CNS immune surveillance
Functional role of skull lymphoid structures in CNS immunosurveillance.
The study investigated how lymphoid structures in skull bone marrow contribute to CNS antigen-specific adaptive immune surveillance in mice. The authors identified skull lymphoid structures with germinal-center features that support immune cell organization and exchange between skull bone marrow and the CNS under homeostatic and disease conditions. This work clarifies a mechanistic route for adaptive immune surveillance of the CNS and suggests skull bone marrow lymphoid niches as potential targets for immunotherapies in CNS disease.
Park JH, Abramishvili D, Davanzo GG et al. · Nature · (2026) · View on PubMed ↗
Sleep & circadian/neurophysiology
Wake-activated neuronal populations that regulate sleep drive.
This study investigated which wake-activated neuronal populations regulate sleep drive in mice using whole-brain activity mapping, targeted neuronal manipulations, and electrophysiology. The key finding was that anterior medial preoptic area and median raphe neurons encode sleep deficit, and activating sleep-deprivation-responsive cells in these regions increases sleep drive. This is significant because it identifies candidate neural circuit nodes for homeostatic sleep regulation, offering targets for understanding and potentially treating sleep disorders.
Joo W, Diester C, Bitsikas V et al. · Nature · (2026) · View on PubMed ↗
Psychedelics align brain activity with context.
This study investigated how psychedelics align brain activity with context by analyzing a large single-site neuroimaging dataset combining fMRI and EEG in 62 adults during rest and naturalistic stimuli. The key finding was that psychedelic brain dynamics reorganize in a context-dependent manner rather than remaining purely desynchronized or entropically disordered, aligning neural activity with the structure of the presented context. This is significant because it links subjective context-dependent experiences to measurable changes in brain organization, informing mechanistic models of psychedelic effects.
Stoliker D, Novelli L, Khajehnejad M et al. · Nature · (2026) · View on PubMed ↗
Sleep-wake control with age and neurodegenerative diseases.
This review synthesized evidence on how aging alters sleep-wake architecture and how sleep disorders relate to neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, progressive supranuclear palsy, Huntington’s disease, and ALS. Across these conditions, shared sleep phenotypes such as difficulty initiating sleep and fragmented sleep are linked to overlapping mechanistic pathways implicated in neurodegeneration. The article highlights sleep as both a clinical marker and a potential therapeutic target to improve outcomes in neurodegenerative disease.
Tang WX, Yang C, Zhang M et al. · Sleep medicine reviews · (2026) · View on PubMed ↗
Neurodegeneration & brain biomarkers
Human brain organoids record the passage of time over multiple years.
This study examined long-term human brain organoid maturation by culturing human brain organoids for 5 years and optimizing conditions to extend excitatory neuron viability. The key finding was that organoids transcriptionally age over multiple years with cell-type specificity, using maturation-associated modules derived from endogenous human brain. This is significant because it creates a more realistic in vitro model of human postnatal brain development across extended timescales.
Faravelli I, Antón-Bolaños N, Wei A et al. · Nature · (2026) · View on PubMed ↗
Cortical thickness changes precede high levels of amyloid by at least 7 years.
The study analyzed longitudinal MRI and amyloid-beta (Aβ) PET data from three cognitively healthy cohorts to determine whether cortical thickness changes predict later conversion to Aβ-positive status. Individuals who later became Aβ-positive showed thicker cortex and reduced cortical thinning detectable up to 7 years before conversion, with effects persisting after accounting for quantitative Aβ levels. This suggests cortical structural trajectories can serve as early, preclinical biomarkers of Alzheimer’s disease risk beyond amyloid burden alone.
Roe JM, Jagust WJ, Landau SM et al. · Nature neuroscience · (2026) · View on PubMed ↗
Neurogenetics & animal models of neurological disease
Astrocytic 4R-tau pathology drives aquaporin-4 (AQP4) mislocalization, glymphatic dysfunction, and neurotransmitter dysregulation in mice.
This mouse mechanistic study used an astrocyte-specific GFAP/tau transgenic model (GFAP/tau Tg; GFAP-e(2A-mMAPT(4R)) cDNA) to test whether astrocytic 4R-tau pathology drives aquaporin-4 (AQP4) mislocalization, glymphatic dysfunction, and neurotransmitter dysregulation. GFAP/tau Tg mice developed robust astrocytic hyperphosphorylated 4-repeat tau and showed downstream disruptions consistent with impaired cerebral fluid transport and altered neurotransmitter regulation. The work is significant because it links PSP-like astrocytic tau pathology to specific glymphatic and AQP4-related mechanisms that could be targeted to modify neurodegeneration.
Lu M, Tian H, Wang J et al. · The Journal of neuroscience : the official journal of the Society for Neuroscience · (2026) · View on PubMed ↗
Berberine alleviates postoperative cognitive dysfunction by suppressing microglial IDO1 induction and kynurenine pathway activation in aged mice.
This preclinical study used a tibial fracture model in aged mice to test whether berberine alleviates postoperative cognitive dysfunction (POCD) by suppressing microglial indoleamine 2,3-dioxygenase 1 (IDO1) induction and downstream kynurenine pathway activation. The key finding was that surgery/anesthesia increased hippocampal pro-inflammatory cytokines and microglial IDO1 activity (raising the kynurenine-to-tryptophan ratio) and caused cognitive impairment, dendritic simplification, and synaptic loss, which were mitigated by berberine. Scientifically, it implicates microglial IDO1 as a mechanistic driver of POCD and positions berberine as a candidate therapeutic modulator of the kynurenine pathway.
Yang J, Liu X, Zhang T et al. · Pharmacological research · (2026) · View on PubMed ↗
Endometriosis-derived iPSCs reveal conserved stromal maturation and endocrine responsiveness.
This work studied induced pluripotent stem cell (iPSC) models derived from patients with endometriosis to model endometrial stromal differentiation and hormone responsiveness. Endometriosis-derived iPSCs followed a defined differentiation trajectory toward stromal-like states and acquired transcriptional responsiveness to endocrine cues, with transcriptomic evidence of conserved stromal maturation programs. The platform enables tractable human mechanistic and translational studies of endometriosis-associated stromal dysfunction and hormone-dependent disease biology.
McDowell H, Sun S, McNally R et al. · Science advances · (2026) · View on PubMed ↗
MAPT splicing modulators reduce 4R tau and rescue tauopathy phenotypes in human neurons and in a mouse model.
This work tested MAPT splicing modulators designed to promote exon 10 exclusion in human neurons and in a mouse model of 4R tauopathy driven by MAPT exon 10 splicing/gain-of-function mechanisms. The modulators reduced 4R tau levels and rescued tauopathy phenotypes in both human neuronal systems and the mouse model. These findings support targeted mRNA splicing as a therapeutic approach for MAPT-driven 4R tau neurodegeneration such as FTD-tau.
Silva MC, Lindmeier H, Pigini P et al. · Science translational medicine · (2026) · View on PubMed ↗
Identification of potent inhibitors of JUN N-terminal kinases for treatment of endometriosis and associated pain.
This study used a DNA-encoded chemical library approach to identify potent, more specific inhibitors of JUN N-terminal kinases (JNKs) for treating endometriosis and associated pain. The key finding was the discovery of JNK inhibitor candidates with improved potency/specificity relative to prior tools, aligning with JNKs as validated nonhormonal targets in preclinical and early clinical settings. More selective JNK inhibition could reduce inflammatory pathology and pain while potentially limiting disease progression in endometriosis patients.
Madasu C, Sirupangi T, Herrera GJ et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Heme-binding protein CYB5D1 couples intraflagellar redox to calcium signaling for coordinated flagellar beating.
This study investigated how the heme-binding axonemal protein CYB5D1 regulates intraflagellar redox and Ca2+ signaling to coordinate flagellar beating, using wild-type and CYB5D1 loss or heme-binding–defective (D58G) conditions. CYB5D1 acted as a redox-sensitive switch controlling flagellar beating coordination by regulating Ca2+ dynamics, and disrupting heme-binding lowered flagellar redox potential and altered Ca2+ spike frequency/amplitude. The results link intraflagellar redox control to calcium-driven motor coordination, advancing mechanistic understanding of ciliary/flagellar synchrony.
Lin Y, Zhao L, Liu G et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Neuronal overexpression of Kcnn1 in A53T α-synuclein mice suppresses phospho-serine 129 α-synuclein formation and doubles survival time.
This study tested whether neuronal overexpression of the mouse calcium-activated potassium channel subunit Kcnn1 modifies disease in Thy1.2-driven A53T human α-synuclein transgenic mice. Kcnn1 overexpression increased median survival from 8.5 to 18 months and shifted disease presentation from rapidly progressive dystonic-like behavior to later-onset, slowly progressive lower limb clasping. The findings identify Kcnn1 as a potential genetic modifier that suppresses phospho-serine 129 α-synuclein formation and slows progression in an A53T α-synuclein model.
Nagy M, Fenton WA, Horwich AL · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Neuropeptide visualization using split GFP in live C. elegans.
This study developed and validated split GFP–based labeling to visualize neuropeptide release in live Caenorhabditis elegans, focusing on two neuropeptides: INS-1 and NLP-40. The authors demonstrate that split GFP can be used in vivo to visualize these neuropeptides released from neurons, addressing limitations of antibody labeling and full-length fluorescent protein fusions. This provides a less perturbative, versatile tool for studying neuropeptide dynamics in living animals.
Aleogho BM, Yokosawa R, Noma K · PloS one · (2026) · View on PubMed ↗
Gene therapy & regenerative medicine
Multimodal evidence for bone lymphatics in skeletal health and repair.
This study investigated the role of bone lymphatics in skeletal health and repair by integrating spatial transcriptomics, single-cell RNA sequencing, and imaging in murine and human bone. The key finding is that Prox1+ lymphatic endothelial cells (LECs) are present in bone and act as positive regulators of bone mass and repair, supported by spatial transcriptomics and reanalysis of multiple scRNA-seq datasets. Scientifically, it reframes bone lymphatics as a functional component of the skeletal microenvironment and suggests new targets for improving bone regeneration.
Yang Y, Zhang Y, Shi Y et al. · Cell · (2026) · View on PubMed ↗
Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial.
The HEAL-CHF early-stage randomized trial studied whether intramyocardial injection of allogeneic human iPSC-derived cardiomyocytes improves safety and feasibility in patients with advanced ischemic heart failure with reduced ejection fraction (≤45%). In 20 randomized patients (all received concomitant CABG), the primary endpoint focused on sustained ventricular tachycardia (1–6 months) and tumorigenicity (12 months), and the abstract reports no sustained ventricular tachycardia in either group. This trial is clinically important as it supports the initial safety profile of allogeneic iPSC-cardiomyocyte cell therapy for myocardial regeneration in advanced ischemic heart failure.
Zhang H, Menasche P, Fan J et al. · Nature medicine · (2026) · View on PubMed ↗
Carboxyl-terminal blockade of sortilin binding enhances progranulin gene therapy in a mouse model of frontotemporal dementia.
This study investigated whether blocking progranulin (PGRN) binding to the sorting receptor sortilin via carboxyl-terminal modification improves progranulin gene therapy efficacy in a mouse model of frontotemporal dementia. In progranulin-deficient mice, gene therapy vectors expressing modified PGRN with reduced sortilin interaction enhanced therapeutic outcomes compared with vectors retaining intact sortilin interactions. The work suggests that targeting the PGRN–sortilin axis can potentiate gene therapy for progranulin insufficiency and refine therapeutic design.
Kashyap SN, Fox SN, DeNittis VR et al. · Science translational medicine · (2026) · View on PubMed ↗
High-resolution mapping of osteoblast metabolism and bone matrix turnover in vivo.
This study developed an integrated in vivo imaging platform combining stable isotope labeling with correlative electron microscopy and nanoscale secondary ion mass spectrometry (NanoSIMS) to map osteoblast metabolism and bone matrix turnover. It showed rapid incorporation of dietary amino acids into osteoblast subcellular compartments within minutes and subsequent deposition of newly labeled extracellular matrix in mineralized tissue. The approach enables nanometer-scale, time-resolved tracking of bone formation dynamics, which can accelerate mechanistic and translational research in bone diseases.
Chen K, Guo J, Chen X et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Immunotherapy & engineered immune cells/antibodies
Design and preclinical characterization of an affinity-tuned BCMA×CD3 bispecific T-cell engager for broad B-cell depletion.
This preclinical mAbs study designed and characterized gamgertamig, an affinity-tuned BCMA×CD3 bispecific T-cell engager, for broad B-cell depletion. The key finding was that gamgertamig uses a humanized IgG4 1+1 bispecific format with Fc-silencing mutations and a reduced-affinity CD3-binding arm to create a >50-fold affinity bias toward BCMA, enabling potent antigen-dependent cytotoxicity. Scientifically, it advances a strategy to balance strong target-dependent killing with controlled T-cell activation for BCMA-directed depletion.
Thomas J, Xu G, Lock H et al. · mAbs · (2026) · View on PubMed ↗
Enhanced antitumor immunity of mRNA vaccines by bioorthogonal-like delayed activation of exogeneous STING.
This study investigated whether an engineered mRNA vaccine adjuvant strategy can enhance antitumor immunity by controlling STING activation, testing in humanized STING mouse models and using human papillomavirus (HPV) contexts. The key finding was that a synchronized STING (Syn-STING) lipid nanoparticle co-delivering antigen mRNA, full-length STING mRNA, and a bioorthogonal-like delayed-release STING activator (DMXAA) enabled localized mouse STING activation while avoiding systemic recognition of endogenous human STING. This is significant because it provides a mechanistically targeted way to overcome limitations of STING agonists as mRNA vaccine adjuvants, potentially improving vaccine efficacy.
Qin P, Qin Q, Hao Y et al. · Nature biotechnology · (2026) · View on PubMed ↗
Gut microbiota generate dinitrosyl iron complexes with cardiometabolic benefits.
This research developed synthetic transcription factors using domain recombination (DESynR; domain engineered via synthesis and recombination) and tested whether DESynR AP-1 transcription factors enhance chimeric antigen receptor (CAR) T cell antitumor function in primary human T cells. The key finding was that DESynR activator protein-1 (AP-1) transcription factors outperformed natural AP-1 TFs across in vitro and in vivo antitumor assays by inducing broad transcriptional/epigenetic reprogramming and optimizing exhaustion, effector/cytotoxic function, and persistence. This is significant for next-generation CAR T engineering because it provides a scalable genetic design strategy to create non-natural T cell states with improved therapeutic performance.
Kleschyov AL, Shimari M, Boeder AM et al. · Cell · (2026) · View on PubMed ↗
A phase 1 feasibility trial of BE-CAR33, an “off-the-shelf” base-edited CAR33 T cell therapy for acute myeloid leukemia.
This phase 1 open-label, nonrandomized, single-center trial evaluated BE-CAR33, an off-the-shelf base-edited anti-CD33 CAR T cell product, in patients with acute myeloid leukemia (AML). BE-CAR33 used multiplexed cytidine deamination to base-edit and disrupt the TRAC, CD52, and CD7 loci to reduce graft-versus-host disease risk and evade immunotherapy effects, and the study assessed safety, feasibility, and antileukemic activity. If effective and safe, this universal donor-derived base-edited CAR strategy could overcome limitations of autologous CAR T manufacturing in heavily pretreated AML patients.
Georgiadis C, Chiesa R, Rashed H et al. · Science translational medicine · (2026) · View on PubMed ↗
Cancer biology, metastasis & tumor microenvironment
Exploring the landscape of targetable alterations in patients with glioblastoma.
This review assessed the landscape of targetable genomic and molecular alterations in glioblastoma and why targeted therapies have shown limited benefit despite deep tumor profiling. It highlights constraints such as intratumoral heterogeneity, pathway redundancy, cellular plasticity, and limited CNS drug delivery, while discussing strategies to improve blood–brain penetration (e.g., focused ultrasonography, convection-enhanced delivery, efflux avoidance, and chemical modifications). The significance is that it frames actionable approaches for matching targeted drugs to glioblastoma alterations while addressing delivery and resistance barriers.
Aquilanti E, Touat M, French P et al. · Nature reviews. Clinical oncology · (2026) · View on PubMed ↗
Honeybadger, a micropeptide encoded by an alternative PVT1 transcript, is a critical negative regulator of RAS-MAPK signaling in MYC-driven tumors.
This study examined the micropeptide Honeybadger, encoded by an alternative PVT1 transcript, and its role in regulating RAS–MAPK signaling in MYC-driven tumors. Honeybadger acted as a critical negative regulator of RAS–MAPK pathway activity in the context of MYC-driven oncogenesis. The finding is significant because it reveals a functional, translation-competent product from the lncRNA locus PVT1 that can modulate a major oncogenic signaling axis and may represent a therapeutic vulnerability in MYC+ cancers.
Paithane U, Tiwari A, Hall B et al. · Genes & development · (2026) · View on PubMed ↗
Firefox, a protein encoded by circular PVT1, is essential for MYC-driven oncogenesis.
This Genes & Development study focused on Firefox, a protein encoded by circular PVT1, and tested its requirement for MYC-driven tumorigenesis. It showed that genomic rearrangements at the PVT1 locus in MYC+ cancers often unbalance translocations that enrich 5’-PVT1 while depleting 3’-PVT1, supporting production of the circular PVT1-derived Firefox protein. The work is significant because it establishes Firefox as essential for MYC-driven oncogenesis, linking specific PVT1 rearrangement architecture to a functional protein driver of cancer.
Tiwari A, Paithane U, Tashiro K et al. · Genes & development · (2026) · View on PubMed ↗
Organ-specific colonization and niche remodeling in a human tissue model of metastasis.
This study developed a human multitissue metastasis model to study organ-specific colonization and niche remodeling, using engineered bone and lung platforms connected by vascular flow carrying circulating cancer cells. MDA-MB-231 cells extravasated to both tissues, remodeled local niches, and adopted transcriptional programs reflecting adaptation to the microenvironment, with bone homing showing particularly consistent behavior with in vivo patterns. The model provides a controllable system to dissect how metastatic cells differentially colonize organs and could accelerate discovery of organ-specific anti-metastatic strategies.
Chramiec AG, Baldassarri I, Öztürk E et al. · Science translational medicine · (2026) · View on PubMed ↗
Repression of ferroptotic cell death mediated antitumor immunity by mitochondrial calcium signaling.
This study examined how mitochondrial calcium signaling regulates ferroptosis and its impact on antitumor immunity, focusing on the mitochondrial calcium uniporter (MCU) and downstream control of GPX4. MCU-dependent acetyl-CoA production supported GPX4 function, and acetylation of GPX4 at lysine 90 (K90) prevented formation of a detri—(truncated in abstract) that would otherwise promote ferroptosis. By repressing ferroptotic cell death through mitochondrial calcium–acetyl-CoA–GPX4 signaling, the pathway can modulate tumor microenvironment immune responses and cancer vulnerability.
Chen J, Zhao B, Dong H et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Neutrophil-intrinsic Vgll4 constrains tumorigenesis by preventing a STAT3/STAT5-driven immunosuppressive switch.
This study identified the Hippo pathway component Vgll4 as a neutrophil-intrinsic regulator of tumor progression, using neutrophil-specific Vgll4 ablation in tumor models. Vgll4 was dispensable for homeostatic granulopoiesis but constrained tumorigenesis by preventing a STAT3/STAT5-driven immunosuppressive switch, with Vgll4 loss increasing tumor growth. Mechanistically, Vgll4 bound STAT3 and STAT5 in a JAK-dependent manner and loss of Vgll4 reduced SOCS3 expression, linking intrinsic neutrophil fate control to antitumor immunity.
Shao L, Yue J, Wang S et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
USP14 competitively binds to FBXW7 to stabilize MTDH and promotes metastasis and drug resistance of head and neck squamous cell carcinoma.
This study investigated how the deubiquitinase USP14 promotes metastasis and drug resistance in head and neck squamous cell carcinoma (HNSCC) by stabilizing metadherin (MTDH). USP14 competitively bound to FBXW7 and deubiquitinated/stabilized MTDH, activating NF-κB signaling to drive epithelial-mesenchymal transition and cancer stem cell maintenance. By revealing the USP14–FBXW7–MTDH axis, the work highlights a mechanistic target for limiting HNSCC metastasis and chemoresistance.
Wang X, Zhou Y, Tan J et al. · Proceedings of the National Academy of Sciences of the United States of America · (2026) · View on PubMed ↗
Virology & antiviral strategies
Identification of a conserved neutralizing epitope on the ASFV H240R protein by a nanobody that inhibits viral attachment.
This study identified a conserved neutralizing epitope on the African swine fever virus (ASFV) H240R protein using a nanobody approach in which a Bactrian camel was immunized with recombinant H240R and an H240R-specific VHH phage-display library was screened. The key finding was the isolation of nanobody H240R-Nb82 that neutralized ASFV by inhibiting viral attachment and bound a conserved epitope on H240R. This is scientifically and translationally significant because it provides a candidate neutralizing reagent and epitope target to support ASFV vaccine or therapeutic development.
Jiao D, Ren B, Liu D et al. · The Journal of biological chemistry · (2026) · View on PubMed ↗
RNA structures regulate norovirus life cycle and enable rational attenuation in vivo.
The study mapped and functionally tested structured RNA elements across the murine norovirus genome in an infection context using orthogonal in-cell chemical probing. Disrupting specific conserved RNA structural elements reduced viral replication in cell culture and modulated translation in cis, enabling rational attenuation in vivo. These findings establish a systematic framework for targeting viral RNA structures to control norovirus fitness and potentially reduce immune recognition during infection.
Hann T, Ökten AB, Filler RB et al. · Cell · (2026) · View on PubMed ↗
A bispecific antibody targeting conserved hemagglutinin epitopes confers broad protection against H7 avian influenza and accelerates viral clearance via localized respiratory delivery.
The study engineered a bispecific antibody targeting conserved hemagglutinin (HA) epitopes of H7 avian influenza and tested its protective efficacy using antigenic mapping and longitudinal analysis of over 2,500 viral isolates. Conserved HA head residues (including G70, G132, N167, and M173) were used to design the bispecific construct, which conferred broad protection against H7 viruses and accelerated viral clearance via localized respiratory delivery. This provides a rational antibody design strategy to overcome HA head escape and improve respiratory-targeted antiviral clearance for H7 influenza.
Wu H, Yang F, Wang P et al. · Emerging microbes & infections · (2026) · View on PubMed ↗
Host-pathogen interactions & infection biology
Pervasive phosphorylation by phage T7 kinase disarms bacterial defences.
This study investigated how bacteriophage T7 counters bacterial defenses using protein phosphorylation, focusing on the phage-encoded kinase T7K and its effects during infection in Escherichia coli. The key finding was that T7K is a hyperpromiscuous dual-specificity kinase that phosphorylates nearly all host and phage proteins, producing a phosphorylation scale far exceeding known E. coli phosphosites and disarming defenses broadly rather than specifically. This is significant because it reveals a general anti-defense strategy that can reshape understanding of phage–bacteria arms races and inform antibacterial/phage engineering approaches.
Bartolec T, Mitosch K, Potel C et al. · Nature · (2026) · View on PubMed ↗
A genome-wide CRISPR knockout screen identified host genes essential for Brucella invasion and intracellular survival.
Using a genome-wide CRISPR knockout screen in human THP-1 macrophages, the study identified host genes required for Brucella invasion and intracellular survival. Knockouts of WDR4, ZNF532, or MTHFD1 significantly restricted Brucella invasion and early intracellular survival, and additional hits (e.g., TRAPPC2) further impaired intracellular processes. These host-factor discoveries reveal potential therapeutic targets to limit Brucella infection by disrupting host pathways essential for bacterial persistence.
Wang X, Wu S, Ding Y et al. · Emerging microbes & infections · (2026) · View on PubMed ↗
Immunology, inflammation & immune signaling pathways
RAD51 stabilizes neutrophil extracellular traps to compartmentalize inflammation.
This study investigated how RAD51 regulates neutrophil extracellular trap (NET) architecture and inflammation by using pharmacological inhibition and genetic perturbations (RAD51 knockdown, and GEN1 and RuvC resolvase treatment) in models including murine pulmonary Aspergillus fumigatus infection. The key finding is that RAD51 mediates NET branching by generating DNA junctions, and inhibiting RAD51 dismantles NETs and reduces lung cytokines while shifting NET components to the circulation that can induce IL-6. Clinically and mechanistically, targeting RAD51 may modulate NET-driven inflammatory pathology, though systemic cytokine effects must be considered.
Tsansizi LI, Guan SY, Aramburu IV et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗
Beyond Histamine: Mast Cell-Neuron Communication in Chronic Pruritic and Pain Disorders.
This review synthesized evidence on mast cell–neuron communication in chronic pruritic and pain disorders, moving beyond histamine-centric models. The key finding is that non-histaminergic mast cell mediators (e.g., proteases, cytokines, lipid mediators, and neurotrophins) drive bidirectional neuroimmune signaling and feed-forward amplification that sustain itch and pain. This provides a unifying mechanistic framework that can inform development of targeted therapies for chronic itch and cutaneous pain.
Kagan T, Yosipovitch G · Experimental dermatology · (2026) · View on PubMed ↗
A biased allosteric modulator is a molecular glue for β2AR dimerization.
This study investigated whether a biased allosteric modulator can act as a molecular glue to stabilize GPCR dimerization, focusing on β2-adrenergic receptor (β2AR) homodimers. The key finding was that AP-7-168, an optimized derivative of a β-arrestin-biased negative allosteric modulator, stabilizes β2AR homodimerization, with cryogenic electron microscopy revealing a unique binding mode where two AP-7-168 molecules pack within a transmembrane-helix pocket. This is significant because it provides a structure-guided strategy for therapeutically targeting GPCR dimerization with potential implications for designing next-generation modulators.
Shen J, Peddada TN, Komolov KE et al. · Nature · (2026) · View on PubMed ↗
Alpha protein kinase 3 gene therapy restores heart function in mouse and human models of cardiomyopathy.
The study tested an AAV-mediated gene replacement delivering full-length human ALPK3 in neonatal and adult mouse models of ALPK3-truncating cardiomyopathy and in human disease models. AAV-ALPK3 prevented disease in neonatal Alpk3-mutant mice and reversed established pathology in adults, with proteomic analyses showing reversal of >95% of the molecular disease signature. These findings support ALPK3 as a tractable therapeutic target and provide preclinical-to-translational rationale for AAV gene therapy in severe cardiomyopathy.
McNamara JW, Keen EB, Sutton R et al. · Nature cardiovascular research · (2026) · View on PubMed ↗
Noncircadian BMAL1-YAP activity amplifies persistent inflammation in aged epidermis.
The study examined how aging alters inflammatory transcriptional programs in murine epidermis, focusing on BMAL1-YAP cooperation independent of BMAL1’s circadian clock function. In aged epidermis, BMAL1 partnered with the mechanosensitive cofactor YAP at inflammation-related enhancers to amplify target gene transcription and persistent inflammation. This identifies a noncircadian BMAL1–YAP enhancer mechanism as a potential molecular lever to reduce chronic inflammatory skin aging.
Bonjoch J, Solá P, García-Mulero S et al. · Nature aging · (2026) · View on PubMed ↗
Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.
This systematic review synthesized randomized trials and observational studies measuring anti-drug antibodies (ADAs) in adults with psoriatic arthritis (PsA) treated with biological disease-modifying antirheumatic drugs (bDMARDs). Across included studies, the review assessed ADA prevalence and tested associations with serum drug trough levels, clinical efficacy, and safety outcomes. Clinically, quantifying ADA frequency and impact in PsA supports evidence-based decisions about therapeutic drug monitoring and switching strategies when immunogenicity undermines bDMARD effectiveness or tolerability.
Kimpton J, Akpabio A, Watts A et al. · RMD open · (2026) · View on PubMed ↗
Intestinal flagellin drives multisystem inflammation through TLR5-IL-15-ARA axis.
This study investigated how intestinal flagellin triggers multisystem inflammation via a TLR5–IL-15–ARA axis, using comparative metagenomic analyses across long COVID, rheumatoid arthritis (RA), ankylosing spondylitis (AS), and inflammatory bowel disease (IBD) cohorts. It identified gut-driven inflammatory signaling patterns that converged across these systemic inflammatory diseases, with long COVID used as a postdysbiotic, treatment-naïve model to connect microbial signals to host immune pathways. The mechanistic cross-disease linkage is significant because it supports targeting the TLR5–IL-15–ARA pathway to reduce systemic inflammation originating from the gut.
Geng J, Zhu Y, Chen S et al. · Gut · (2026) · View on PubMed ↗
Synthetic transcription factors designed by domain recombination enhance CAR T cell antitumor function.
This study used single-cell immune profiling to analyze T cells from supercentenarians to determine whether CD4 cytotoxic T lymphocytes (CD4 CTLs) expand during healthy aging. The key finding was that CD4 CTLs begin to expand around age 100, show sequential CD27/CD28 loss without exhaustion, and are dominated by large clones consistent with repeated stimulation by persistent antigens. Scientifically, it supports adaptive immune expansion as a feature of healthy extreme longevity and suggests antigen-driven clonal dynamics, including TCR sequence overlap with tumor-expanded T cells.
Takacsi-Nagy O, Kasinathan S, Hartman A et al. · Cell · (2026) · View on PubMed ↗
Mitochondrial profiling across macrophage states reveals inhibition of IL-4/IL-13 reprogramming by the integrated stress response.
This study profiled macrophage mitochondrial remodeling by integrating transcriptomics with whole-cell and purified mitochondrial proteomics in macrophages stimulated with lipopolysaccharide (LPS)/interferon-γ (IFN-γ) or interleukin-4 (IL-4)/IL-13, focusing on STAT6-dependent effects. It found a disconnect between mitochondrial mRNA and protein levels and identified that STAT6 signaling drives increased mitochondrial DNA (mtDNA), while IL-4/IL-13 reprogramming is inhibited by the integrated stress response. Scientifically, it links mitochondrial regulation to cytokine-driven macrophage state transitions and highlights the integrated stress response as a brake on IL-4/IL-13 reprogramming.
Blanco-Fernandez J, Lisci M, Foged MM et al. · Science advances · (2026) · View on PubMed ↗
H3.3 chaperone Hira primes the effector program and function of regulatory T cells.
This study examined how the histone variant H3.3 and its chaperone Hira regulate regulatory T cell (Treg) differentiation into effector Tregs (eTregs) in mice. Treg-specific deletion of Hira reduced the eTreg population, impaired suppressive function, and caused multi-organ inflammation, with Hira-dependent H3.3 deposition establishing an effector-associated epigenetic program. These findings identify Hira/H3.3 as a key epigenetic regulator of Treg effector function, informing potential targets to modulate immune tolerance.
Cao X, Lv M, Lv Z et al. · Science advances · (2026) · View on PubMed ↗
A population-scale transcriptional atlas of blood and tissue in lupus nephritis.
This study generated a population-scale single-cell/single-nuclear transcriptional atlas from kidney biopsies of 155 patients with lupus nephritis (LN) and 30 preimplantation transplant biopsy controls, alongside 327,326 single-cell blood profiles. LN pathological features were linked to specific stromal and immune cell states, including cell states that were tissue-specific versus those shared with blood. The atlas provides a high-resolution cellular map that can guide mechanism-focused biomarkers and stratification of LN subtypes for future precision therapies.
Sugiarto NW, Gurajala S, Curtis M et al. · Science translational medicine · (2026) · View on PubMed ↗
Heme acts as a metabolic brake on erebosis in the Drosophila gut.
This work investigated how the small metabolite heme regulates erebosis, a nonapoptotic/nonautophagic/nonnecrotic cell death process, in Drosophila gut enterocytes using single-cell RNA sequencing and genetic approaches. Cells undergoing erebosis up-regulate heme-degrading activity, and heme functions as a metabolic brake on erebosis, indicating that heme availability modulates the death pathway. Scientifically, it connects metabolic state to a specific regulated cell-death program, informing how tissue homeostasis balances enterocyte survival and loss.
Morikawa M, Hayashi T, Ikegawa Y et al. · PLoS biology · (2026) · View on PubMed ↗
Metabolism, immunometabolism & microbiome
Unveiling the Immune Mechanisms of Hypertension With Single-Cell Transcriptome-Wide Mendelian Randomization.
This study used single-cell transcriptome-wide Mendelian randomization to investigate immune mechanisms of hypertension by integrating eQTLs for genes expressed in 14 immune cell subsets (OneK1K) with two-sample MR and colocalization using FinnGen and UK Biobank. The key finding is that a tiered framework can prioritize cell type-specific causal eGenes for hypertension and related complications, and the abstract indicates that prioritized genes were assessed for druggability, but specific genes and results are not provided due to truncation. The significance is that it helps identify immune-cell targets with causal support for potential therapeutic development in hypertension.
Mao Y, Li P, Cheng C et al. · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · (2026) · View on PubMed ↗
Cumulative C-reactive protein exposure links to COPD risk in adults with cardiovascular-kidney-metabolic syndrome stages 0-3 (no overt CVD): A prospective cohort study.
This prospective cohort study investigated whether cumulative exposure to C-reactive protein (CRP) predicts COPD risk in adults aged ≥45 years with cardiovascular-kidney-metabolic (CKM) syndrome stages 0–3 (no overt CVD) using CHARLS data. The key finding is not available because the abstract is truncated before results are reported. If cumulative CRP exposure is predictive, it would support using longitudinal inflammation biomarkers to stratify COPD risk in CKM populations before overt cardiovascular disease.
Liu Y, Gong J, Zhang J et al. · Science progress · (2026) · View on PubMed ↗
Intestinal cGAS-STING-IFN signalling promotes obesity by downregulating microbiota-derived IAA in male mice.
The study investigated intestinal cGAS–STING–IFN signaling as a driver of obesity by modulating microbiota-derived indole-3-acetic acid (IAA) in male mice and assessed relevance to humans with obesity. Intestinal cGAS activation increased type I interferon production, and epithelial-cell–specific cGAS deletion enhanced energy expenditure, protected against diet-induced obesity, and improved metabolic health in a microbiota-dependent manner. The work links gut innate immune sensing (cGAS) to metabolic regulation via downregulation of microbiota-derived IAA, identifying a potential immunometabolic intervention axis.
Deng J, Meng W, Yang Y et al. · Nature metabolism · (2026) · View on PubMed ↗
CD4 CTLs in supercentenarians: Signs of adaptive expansion in healthy aging.
This study investigated how gut microbes generate mobile dinitrosyl iron complexes (DNICs) from inorganic nitrate and non-heme iron and how this affects host cardiometabolic physiology in mice and humans. Using electron paramagnetic resonance, the authors detected DNICs in tissues of conventional but not germ-free mice, and showed that feces and E. coli could generate DNICs from nitrate plus iron citrate, with nitrate-reductase deficiency preventing DNIC formation. The key significance is that DNIC production links diet–microbiome chemistry to systemic metabolic benefits, supported by improvements in cardiometabolic dysfunction after nitrate+iron citrate or DNIC supplementation.
Hashimoto K, Kojima-Ishiyama M, Inokuchi H et al. · Cell reports · (2026) · View on PubMed ↗
Multiomics profiling of plasma reveals lipid-immune dysregulation and exosome remodeling in mpox and mpox-HIV co-infection.
The study used quantitative plasma lipidomics and metabolomics, alongside exosome proteomics, cytokine profiling, and exosome-treated HepG2/A549 transcriptomics, to characterize immunometabolic and exosome remodeling differences in patients with mpox, mpox-HIV co-infection, and HIV alone. MPox and mpox-HIV co-infection showed lipid-immune dysregulation and distinct exosome remodeling signatures compared with controls and HIV monoinfection, with functional interpretation supported by exosome effects on hepatocyte- and lung-derived cell models. This multiomics approach clarifies how HIV co-infection alters MPXV-associated immunometabolism and identifies exosome-associated pathways that may be actionable for co-infection management.
Yong S, Zhang J, Tian H et al. · Med (New York, N.Y.) · (2026) · View on PubMed ↗
A bacterial enzyme enhances both energy metabolism and health across the life span of C. elegans and mice.
This study tested whether expressing the bacterial lipoic acid protein ligase A (LplA) can enhance energy metabolism and healthspan across the lifespan in Caenorhabditis elegans and mouse models. LplA expression increased energy metabolism and improved health outcomes over the lifespan while maintaining low oxidative stress without apparent tradeoffs. The results support LplA as an orthogonal molecular tool to decouple metabolic enhancement from oxidative damage, with implications for aging and metabolic intervention strategies.
Liu Y, Hu Z, Duan D et al. · Science advances · (2026) · View on PubMed ↗
Cardiovascular disease & vascular risk
Tracing the origins of de novo coronary collateral formation in cardiac repair.
This study examined the cellular origins of de novo coronary collateral formation during cardiac repair using genetic lineage tracing in which arterial endothelial cells and capillary endothelial cells were tracked. The key finding is that capillary endothelial cells, not arterial endothelial cells, are the major building blocks for de novo collateral arteries, and transient Vegfa expression delivered via modified mRNA markedly promotes collateral formation. These results identify capillary-to-collateral conversion and VEGFA as mechanistic levers for therapeutic strategies to enhance collateral growth after ischemic injury.
Zhang M, Han M, Hou Y et al. · Science (New York, N.Y.) · (2026) · View on PubMed ↗
Triple versus double antithrombotic therapy after PCI in atrial arrhythmia: a real-world comparative analysis based on initial antithrombotic strategy using TriNetx.
This retrospective TriNetX real-world comparative analysis studied triple versus double antithrombotic therapy after percutaneous coronary intervention (PCI) in adults (≥18 years) with atrial fibrillation/flutter across coronary artery disease phenotypes. The key finding was that outcomes differed by initial strategy (triple therapy vs double therapy) after propensity-score matching, informing the risk–benefit balance of adding dual antiplatelet therapy on top of anticoagulation. Scientifically and clinically, the study helps guide post-PCI antithrombotic selection in atrial arrhythmia patients where optimal regimens remain uncertain.
Elnaggar K, Hamza M, Ali Malik S et al. · Future cardiology · (2026) · View on PubMed ↗
Association Between Cardiovascular-Kidney-Metabolic Health and Early Arterial Injury in Young Adults in the United States: The Future of Families-Cardiovascular Health Among Young Adults Study.
This FF-CHAYA (Future of Families-Cardiovascular Health Among Young Adults) study examined how American Heart Association Cardiovascular-Kidney-Metabolic (CKM) syndrome staging relates to cardiovascular health (Life’s Essential 8) and early carotid artery injury in young adults in the United States. The key finding was that CKM staging correlated with worse cardiovascular health metrics and with measures of early arterial injury. This supports CKM staging as a potentially useful framework for identifying early vascular risk in young adults before overt disease develops.
Krishnan V, Ning H, Notterman DA et al. · Circulation. Population health and outcomes · (2026) · View on PubMed ↗
Renal disease & kidney therapeutics
Evaluating sparsentan for the treatment of focal segmental glomerulosclerosis.
This review evaluated sparsentan, a dual endothelin receptor A and angiotensin II type 1 receptor antagonist, as an antiproteinuric therapy for focal segmental glomerulosclerosis (FSGS) in the context of primary FSGS and persistent proteinuria despite optimized supportive care and immunosuppression. The key finding is that endothelin-1 biology supports a rationale for sparsentan’s mechanism and that it has emerged as a novel option specifically targeting proteinuria in FSGS. Clinically, this positions sparsentan as a potential next-line therapy for patients with ongoing proteinuria and progressive kidney function decline, addressing an unmet need in FSGS management.
Juanet C, Soler MJ, Zand L et al. · Expert opinion on pharmacotherapy · (2026) · View on PubMed ↗
Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real-Life Experience From a National Reference Network.
This real-life retrospective study from the French PRISIS national reference network evaluated metabolic and renal effects of sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) in patients with genetic lipodystrophy, including familial partial lipodystrophy (n=57) and congenital generalized lipodystrophy (n=2). Over short-term follow-up (mean ~12.5 months) and longer-term follow-up (mean ~29 months), the study reported changes in metabolic parameters including body mass index and related clinical/biochemical outcomes after SGLT2 inhibitor initiation. The findings are significant because they provide pragmatic evidence for using SGLT2 inhibitors in rare, high-risk genetic lipodystrophy populations where randomized data are limited.
Robert L, Belalem I, Vigouroux C et al. · Diabetes, obesity & metabolism · (2026) · View on PubMed ↗
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.
This retrospective target trial emulation using the TriNetX global network compared tirzepatide versus injectable semaglutide for preventing major adverse liver outcomes (MALO) in adults with overweight/obesity and type 2 diabetes. After propensity score matching and ~17 months median follow-up, there was no significant difference in time-to-first MALO between tirzepatide and semaglutide initiators. Scientifically and clinically, the study informs comparative effectiveness of two incretin-based therapies on clinically meaningful liver endpoints (cirrhosis, decompensation, and hepatocellular carcinoma) in a real-world diabetes population.
Banerjee M, Roy A, Sharma VM et al. · Obesity (Silver Spring, Md.) · (2026) · View on PubMed ↗
Urea transporter B-mediated urea uptake-induced protein carbamylation in platelets underlies bleeding in chronic kidney disease.
This study examined how urea transporter B (SLC14A1/UT-B)-mediated urea uptake leads to protein carbamylation in platelets and contributes to bleeding in chronic kidney disease (CKD). It found UT-B expression in human and mouse platelets, linked SLC14A1 single-nucleotide polymorphisms to bleeding events in a CKD cohort, and showed in 5/6 nephrectomy mice that UT-B-driven urea influx underlies platelet dysfunction through carbamylation mechanisms. Scientifically and clinically, it identifies SLC14A1/UT-B and carbamylation as mechanistic drivers of CKD-associated bleeding and potential therapeutic targets.
Qiu Z, Xiong F, Wang Z et al. · Science translational medicine · (2026) · View on PubMed ↗
Clinical guidelines, trials & real-world care delivery
Head positioning after endovascular therapy for acute stroke due to large vessel occlusion (HeadSOAR): multicentre randomised controlled trial.
This multicentre randomised controlled trial studied whether elevating head position to 30–40° versus keeping it flat at 0–10° improves functional outcomes in 1368 adults with acute ischaemic stroke from anterior circulation large vessel occlusion who achieved successful reperfusion after endovascular thrombectomy. The key finding is not available because the abstract is truncated before results are reported. If elevated head positioning improves outcomes, it would provide a simple, immediately implementable post-endovascular care strategy for patients with large-vessel occlusion stroke.
Yuan Z, Peng J, Gu L et al. · BMJ (Clinical research ed.) · (2026) · View on PubMed ↗
Baveno VIII - Advancing Consensus in Portal Hypertension.
Baveno VIII is an expert consensus review that studied and updated evidence-based guidance for advanced chronic liver disease and portal hypertension, building on prior Baveno conferences and focusing on clinically significant portal hypertension (CSPH) and prevention of decompensation. The key finding is that the consensus framework has evolved toward risk stratification and updated clinical recommendations, but specific guideline statements are not included in the truncated abstract. Clinically, Baveno VIII aims to standardize diagnosis and management of portal hypertension to reduce progression to decompensation and related complications.
Journal of hepatology · (2026) · View on PubMed ↗
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
This multicentre, open-label phase 3 trial studied whether liver resection after response to systemic therapy improves survival in treatment-naive patients with locally advanced hepatocellular carcinoma characterized by macrovascular invasion and no extrahepatic metastasis, comparing induction atezolizumab plus bevacizumab followed by resection versus maintenance therapy. The key finding is not available because the abstract is truncated before outcome results are reported. If resection confers a survival advantage, it would support a new treatment pathway for selected advanced HCC patients responding to atezolizumab and bevacizumab.
Sun HC, Zhu XD, Shen F et al. · Lancet (London, England) · (2026) · View on PubMed ↗
Reproductive outcomes after hysteroscopic myoma resection and septal surgery in infertile women - a retrospective study.
This retrospective monocentric cohort study evaluated reproductive outcomes after hysteroscopic myoma resection and hysteroscopic septal surgery in infertile women, comparing pregnancy and live birth rates before versus after surgery and stratifying uterine septa by extent (mild, moderate, sub-/total). The key finding is not available because the abstract is truncated before reporting the quantitative outcomes. If surgery improves pregnancy and live birth rates, it would support clinical decision-making for hysteroscopic management of uterine septa and myomas in infertility.
Drogosch L, Adams J, Rahimi G et al. · Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · (2026) · View on PubMed ↗
Efficacy and Safety of Enfortumab Vedotin by Trial Eligibility in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.
This multicenter real-world retrospective study evaluated the efficacy and safety of enfortumab vedotin (EV) in 180 patients with advanced urothelial carcinoma, comparing trial-eligible versus trial-ineligible groups defined by modified EV-301 eligibility criteria (including eGFR <30 mL/min/1.73 m², poor performance status, and anemia). The key finding was that EV outcomes and tolerability in trial-ineligible patients could be characterized in routine practice despite exclusion from pivotal trials. Clinically, the results inform whether EV can be used more broadly in patients with renal impairment or other high-risk features that were underrepresented in registration studies.
Wakita N, Hara T, Tobe T et al. · International journal of urology : official journal of the Japanese Urological Association · (2026) · View on PubMed ↗
New and novel pharmacotherapies for hemophilia A: an update.
This narrative review updated hemophilia A pharmacotherapies, focusing on recently approved and phase III agents beyond standard and extended half-life factor VIII replacement. The key finding is that new replacement therapy (efanesoctocog alfa) and non-replacement “rebalancing” approaches—such as anti-TFPI monoclonal antibodies (concizumab, marstacimab) and antithrombin-targeting agents—are expanding options to improve trough levels and reduce treatment burden. Scientifically and clinically, it frames how these mechanisms may address persistent limitations of conventional factor VIII regimens and guide future treatment selection.
Giuffrida AC, Focosi D, Bodini M et al. · Expert opinion on pharmacotherapy · (2026) · View on PubMed ↗
Health literacy, self-management, and patient empowerment in hemodialysis patients: A cross-sectional study.
This cross-sectional study of 219 hemodialysis patients from three dialysis centers (Jan–May 2024) evaluated relationships among health literacy, self-management, and patient empowerment using validated scales. The key finding was that these constructs were interrelated, with statistical associations assessed via correlation and multivariable linear regression. Clinically, it supports targeting health literacy and self-management behaviors to improve empowerment and potentially outcomes in chronic hemodialysis care.
Ölmez SN, Turgay G · The International journal of artificial organs · (2026) · View on PubMed ↗
Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non-Irritative Concentrations.
This EAACI guideline update standardized methodology for drug hypersensitivity skin testing for both immediate and non-immediate reactions, including recommended timing windows and concentration considerations. The key finding is that testing timing (e.g., 4–6 weeks for immediate reactions, avoiding late testing beyond 6 months due to false negatives) and standardized reading methods (e.g., ENDA reference intradermal criteria) improve reliability, while patch testing concentration guidance is provided for non-irritative testing. Scientifically and clinically, it improves reproducibility and diagnostic accuracy of skin testing across centers for suspected drug hypersensitivity.
Barbaud A, Garvey LH, Phillips E et al. · Allergy · (2026) · View on PubMed ↗
Real-World Safety of Two Pulsed Field Ablation Catheters for Atrial Fibrillation: A MAUDE Analysis.
This MAUDE database analysis compared real-world safety of two pulsed field ablation (PFA) catheter systems for atrial fibrillation—Affera Sphere-9 (Medtronic) versus Varipulse (Biosense Webster)—using FDA reports after U.S. release. The key finding was that complication reporting differed by catheter type and event classification (device-related vs patient-related), with neurologic events being a notable category in the results. Clinically, these findings help contextualize post-market safety profiles for PFA systems and may inform device selection and surveillance.
Shoura SJ, Singireddy S, Coombes K et al. · Pacing and clinical electrophysiology : PACE · (2026) · View on PubMed ↗
Management of pediatric Crohn’s disease: an ECCO-ESPGHAN guideline update.
This ECCO-ESPGHAN guideline update studied evidence for the management, monitoring, and long-term care of pediatric Crohn’s disease in children and adolescents, using a multidisciplinary expert panel and systematic review of studies from 2018–2024 (with targeted updates through June 2025). The key finding was an updated, evidence-graded set of recommendations for pediatric Crohn’s disease care based on Oxford Centre for Evidence-Based Medicine levels and Delphi consensus. Clinically, it provides an up-to-date European standard to guide treatment selection, monitoring strategies, and long-term follow-up in pediatric Crohn’s disease.
Shouval DS, Hojsak I, Miele E et al. · Journal of Crohn’s & colitis · (2026) · View on PubMed ↗
Update 2026: Management of Small Cell Lung Cancer.
This 2026 update studied current management strategies for small cell lung cancer (SCLC) across patient populations stratified by limited-stage versus extensive-stage disease. The key finding was that limited-stage SCLC should use concurrent platinum–etoposide chemoradiotherapy with consolidation durvalumab after chemoradiotherapy for patients without progression, while extensive-stage SCLC should use platinum–etoposide plus a PD-L1 inhibitor as first-line therapy. Scientifically and clinically, it consolidates emerging therapeutic advances into stage-specific standards intended to improve outcomes in this aggressive neuroendocrine cancer.
Lalla M, Dhillon P, Polat BE et al. · Lung · (2026) · View on PubMed ↗
High-throughput synthesis of DNA fragments by molecular self-assembly of overlapping oligonucleotides.
This study examined a high-throughput DNA synthesis approach for synthetic biology by using molecular self-assembly of overlapping oligonucleotides in vitro coupled with in vivo host-cell DNA repair and cloning. The key finding was that Molecular Self-Assembly Induced Cloning (MSAIC) uses orthogonal self-assembly of overlapping DNA segments to reduce crosstalk and oligo misalignment, enabling one-pot production and recovery/cloning of over 1,000 distinct gene fragments using microchip-based oligonucleotide synthesis. Scientifically, it addresses a major bottleneck in gene synthesis and increases throughput for constructing large DNA libraries.
Wu Z, Sun Z, Jiang S et al. · Nature biotechnology · (2026) · View on PubMed ↗
Family genetic designs in MoBa provide insights into health and functioning.
This study investigated how family genetic designs improve inference about health and functioning using the Norwegian Mother, Father and Child Cohort Study (MoBa). The key finding was that genotyped family data (e.g., nuclear mother–father–child trios) can help address confounding that can bias population-based genome-wide association study estimates from unrelated individuals. Scientifically, it demonstrates the added value of familial designs for more reliable interpretation of genetic associations.
Corfield EC, Shadrin AA, Frei O et al. · Nature · (2026) · View on PubMed ↗
Safety and security of large language models in healthcare.
This article reviewed the safety and security risks of large language models (LLMs) in healthcare, including vulnerabilities in the models themselves and risks during integration into hospital workflows. The key finding is that clinical deployment requires systematic mitigation of both model-level threats (e.g., misuse and security vulnerabilities) and workflow-level hazards (e.g., unsafe interactions with clinicians and systems). The review is significant because it consolidates evidence to guide responsible governance, evaluation, and risk controls before widespread clinical adoption of LLMs.
Clusmann J, Freyer O, Ostermann M et al. · Nature · (2026) · View on PubMed ↗
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.
The study used a modified double-blind Delphi panel of U.S. physicians to reach consensus on optimal bridging therapy selection for patients with relapsed/refractory multiple myeloma undergoing CAR-T therapy. Panelists agreed on key attributes influencing bridging therapy choice, including disease burden/aggressiveness, performance status, comorbidities, line of therapy, age, and frailty. This is clinically significant because it standardizes decision-making for bridging therapy in RRMM CAR-T pathways where evidence is limited and practice varies.
Banerjee R, Hashmi H, Chaudhary PM et al. · Advances in therapy · (2026) · View on PubMed ↗
Large-scale AI-guided liver malignancy diagnosis: multicenter study and a single-arm trial.
The study developed and evaluated LiON, a CE-CT-based AI system for liver malignancy diagnosis, using multicenter training and real-world validation cohorts. LiON was trained on 6,443 patients and retrospectively validated across 22,251 patients, achieving high diagnostic performance for malignancy detection and supporting workflow-compatible multiphase processing with clinical data integration. This is significant because it provides a scalable “safety net” for reducing missed or delayed liver cancer diagnoses in high-volume radiology settings.
Zhang X, Li C, Han X et al. · Nature medicine · (2026) · View on PubMed ↗
Traumatic brain injury outcomes across human development index strata in 29 countries.
This prospective multicountry cohort study (Global Neurosurgical Study-1) evaluated traumatic brain injury (TBI) outcomes across all Human Development Index (HDI) tiers in 2,165 patients from 100 hospitals in 29 countries (2019–2022). Patients differed by HDI stratum, including median age (32 years in high-HDI vs 63 years in very-high-HDI) and injury/management case-mix across operative and nonoperative presentations. The study’s broad, HDI-stratified inclusion of both surgical and nonsurgical TBI improves global generalizability and highlights where disparities in TBI burden and outcomes may require targeted health-system interventions.
Nugent JG, Tan H, Stedelin B et al. · Nature medicine · (2026) · View on PubMed ↗
Clinical Outcomes of Metastatic Urothelial Carcinoma Patients Discontinuing Enfortumab Vedotin Due to Toxicity and/or Clinical Response.
This retrospective clinical outcomes study analyzed 147 patients with metastatic urothelial carcinoma (mUC) who received at least two cycles of enfortumab vedotin (EV) alone or EV plus pembrolizumab (EV/P) and then discontinued EV due to toxicity and/or response. The primary endpoint was treatment-free interval (TFI) among patients stopping EV for ≥8 consecutive weeks after achieving complete or partial response (CR/PR) and/or toxicity, with consideration of competing risks and continued pembrolizumab in the EV/P group. The results are clinically important because they characterize durability of disease control after EV discontinuation, informing treatment de-escalation strategies in mUC.
Li J, Fredette J, Dhanikonda N et al. · Clinical genitourinary cancer · (2026) · View on PubMed ↗
Engineering RNA-guided bridge recombinases for precise large-scale genome editing.
This engineering study developed an RNA-guided bridge recombinase system using rational mutagenesis and AI-assisted directed evolution to enable programmable large-scale genome editing in plant and mammalian cells. The optimized system increased editing activity up to 29.8-fold and mediated precise chromosomal rearrangements (deletions, insertions, inversions) from 1.8 to 315 kb in plants, including stable editing efficiencies up to 23.9% in regenerated rice. The work is significant because it expands the toolkit for precise, large-fragment genome editing beyond current multicomponent constraints, with demonstrated agricultural applications such as herbicide resistance.
Gao R, Wei J, Sun C et al. · Trends in biotechnology · (2026) · View on PubMed ↗
Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1).
This article describes the first-in-class orexin receptor 2 (OX2R) agonist oveporexton (TAK-861) for narcolepsy type 1 (NT1) in the context of its approval and mechanism-based treatment of orexin deficiency. Oveporexton is an orally administered, selective OX2R agonist intended to restore unstable sleep-wake regulation driven by loss of orexin-producing neurons. Clinically, this represents a shift from symptomatic therapy toward targeted orexin-pathway modulation for NT1.
Sun Y, Gao J · Drug discoveries & therapeutics · (2026) · View on PubMed ↗
Regional Collaboration with Home Care Physicians is Associated with a Lower Proportion of In-hospital Deaths in Peritoneal Dialysis patients: A Single-center Retrospective Observational Study.
This single-center retrospective observational study compared peritoneal dialysis (PD) patients’ place and cause of death before and after strengthening regional collaboration with home care physicians (early: Jan 2008–Jun 2022; late: Jul 2022–Dec 2024). The key finding was that enhanced home-care physician collaboration was associated with a lower proportion of in-hospital deaths among PD patients. This supports a care-delivery strategy to better align end-of-life outcomes with patients’ preferences in Japan.
Oka H, Yamada S, Ota K et al. · Internal medicine (Tokyo, Japan) · (2026) · View on PubMed ↗
Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% as Maintenance Therapy for Japanese Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: A Phase 3, Open-label Clinical Trial.
This phase 3, multicenter, open-label trial evaluated hyaluronidase-facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) as maintenance therapy in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). fSCIG 10% was administered at each patient’s prior intravenous immunoglobulin (IVIG) dose and interval, with relapse rate as a primary endpoint. If effective and safe as reported, this provides a practical subcutaneous alternative to IVIG for long-term management of these immune-mediated neuropathies in Japan.
Kuwabara S, Shibuya K, Tomizawa Y et al. · Internal medicine (Tokyo, Japan) · (2026) · View on PubMed ↗
Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial.
The ITACS trial studied whether intravenous iron 1000 mg given 1–26 weeks before elective cardiac surgery reduces red blood cell transfusion needs and improves recovery in 955 adults with preoperative anaemia across 33 hospitals in 10 countries. Participants were randomized in a double-blind, placebo-controlled design to intravenous iron versus placebo. The results are clinically significant because they test a potentially transfusion-sparing, perioperative optimization strategy for anaemia in cardiac surgery patients.
Myles PS, Klein AA, Smith JA et al. · BMJ (Clinical research ed.) · (2026) · View on PubMed ↗
Mepolizumab and Dupilumab Show No Significant Difference in Reducing Exacerbations in Patients with COPD and an Eosinophilic Phenotype: Matching-Adjusted Indirect Treatment Comparison.
This study compared the comparative efficacy of two type 2 inflammation biologics—mepolizumab versus dupilumab—in COPD patients with an eosinophilic phenotype using a matching-adjusted indirect treatment comparison (MAIC) of pooled data from three phase 3 randomized placebo-controlled trials. The key finding was that there was no significant difference between mepolizumab and dupilumab in reducing COPD exacerbations and improving health-related quality of life in this population. Clinically, this suggests similar exacerbation benefit between these two biologics for eosinophilic COPD when direct head-to-head evidence is not available.
Bourbeau J, Min J, Kolterer S et al. · Chest · (2026) · View on PubMed ↗
Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management.
This article provides an EASL multidisciplinary guidance for screening and managing steatotic liver disease (SLD), including metabolic dysfunction-associated SLD (MASLD), MetALD (MASLD with increased alcohol intake), and alcohol-related liver disease (ALD), using a patient-trajectory framework. It emphasizes cross-disciplinary coordination across healthcare levels to standardize identification, risk stratification, and management pathways for SLD. Clinically, the guidance aims to reduce fragmentation in care and improve early detection and appropriate treatment across diverse practice settings.
Brouwer WP, Vonghia L, Thiele M et al. · JHEP reports : innovation in hepatology · (2026) · View on PubMed ↗
Paclitaxel oral solution versus paclitaxel injection as second-line therapy for advanced gastric cancer: a multicenter, open-label, randomized phase III trial.
In a multicenter, open-label randomized phase III trial, patients with unresectable/recurrent/metastatic advanced gastric cancer progressing after fluoropyrimidine-based first-line therapy were assigned to oral paclitaxel solution versus paclitaxel injection as second-line treatment. The trial evaluated dual primary endpoints including progression-free survival (PFS) using specified dosing schedules for oral (200 mg/m2 twice daily on days 1, 8, and 15 of a 28-day cycle) versus injection (175 mg/m2 on day 1 of a 21-day cycle). If oral paclitaxel demonstrates non-inferior or superior efficacy with practical advantages, it could change second-line treatment options for advanced gastric cancer.
Li J, Huang M, Deng T et al. · ESMO open · (2026) · View on PubMed ↗
Paternal Valproate Exposure and Offspring Neurodevelopmental Outcomes.
This nationwide Taiwan birth cohort study assessed whether paternal valproate exposure during spermatogenesis (and other antiseizure medications) is associated with neurodevelopmental disorder and congenital malformation risks in offspring. Paternal exposure to valproate during sperm development was evaluated as a potential risk factor using linked national health insurance data for births from 2001–2016 followed through 2021. The results address an evidence gap beyond Nordic populations and inform counseling and risk assessment for paternal antiseizure medication exposure.
Feng YA, Lin MC, Tseng CH et al. · Neurology · (2026) · View on PubMed ↗
Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.
This article reviews and contextualizes the 2024 McDonald criteria for multiple sclerosis (MS) diagnosis, focusing on earlier diagnosis and reducing misdiagnosis in a global implementation setting. It highlights that the 2024 revisions introduce new diagnostic pathways and paraclinical tools intended to improve diagnostic accuracy while enabling earlier initiation of immunomodulatory therapy. Scientifically and clinically, it underscores the need for expertise and careful application to balance speed of diagnosis with avoidance of incorrect MS labeling worldwide.
Solomon AJ, Brownlee WJ, Viswanathan S et al. · Neurology · (2026) · View on PubMed ↗
Efficacy and Safety of Peroral Endoscopic Myotomy (POEM) for Achalasia in Post-Bariatric Surgery Patients: A Systematic Review and Meta-Analysis.
This systematic review and meta-analysis evaluated peroral endoscopic myotomy (POEM) for achalasia in patients who had previously undergone bariatric surgery. Across included bariatric-achalasia studies, POEM showed high technical success and improved dysphagia/achalasia symptoms with an acceptable safety profile despite altered anatomy. These findings support POEM as a feasible minimally invasive option for treating achalasia in the post-bariatric population and justify further prospective comparative studies.
Mahmoud Genidy A, Hamzeh Hamzeh L, Mohammad AbuHawas D et al. · Journal of gastrointestinal and liver diseases : JGLD · (2026) · View on PubMed ↗
American Society of Hematology 2026 Guidelines for Immune Thrombocytopenia (ITP): Initial and Second-Line Therapy in Adults with Primary ITP.
These ASH 2026 guidelines studied evidence for initial and second-line treatment strategies in adults with primary immune thrombocytopenia (ITP). The guideline update synthesizes newly completed trials and emerging therapies since the 2019 ASH ITP guideline to refine recommended treatment pathways for adult patients. Clinically, it provides an updated, evidence-based framework to select first- and subsequent-line therapies for primary ITP and standardize care.
Cuker A, Terrell DR, Sowdagar H et al. · Blood advances · (2026) · View on PubMed ↗
Cell-free DNA fragmentome analysis informs pregnancy outcome in patients with immune-mediated disease.
This study analyzed cell-free DNA (cfDNA) fragmentomics in 1910 first-trimester blood samples from pregnant individuals at high risk of adverse pregnancy outcomes due to twinning, a preexisting immune-mediated disease (IMD), or cytomegalovirus infection. cfDNA fragmentome features informed pregnancy outcome risk stratification earlier in gestation than conventional clinical risk factors. Clinically, it supports prenatal cfDNA fragmentomics as a potential early biomarker to triage high-risk pregnancies and guide escalation of care.
Stanley KE, Lannoo L, Souche E et al. · Science translational medicine · (2026) · View on PubMed ↗
Overlooked and undertreated: Hearing loss among individuals with intellectual disabilities - A German cohort study.
This German cohort study (HörGeist) evaluated an outreach program for hearing screening, diagnostics, intervention, and monitoring in individuals with intellectual disabilities (ID) to address high rates of overlooked hearing loss. The report describes baseline and post-program ear/hearing care status and compares outcomes with standard care and a clinic-based invitation model in 1053 participants aged 1–90 years. Clinically, it tests feasibility and barriers for implementing more universal hearing healthcare in people with ID, aiming to reduce undertreatment and improve hearing outcomes.
Neumann K, Schwalen AS, Gietmann C et al. · PLOS global public health · (2026) · View on PubMed ↗
Generated automatically on August 21, 2026 from PubMed’s trending articles. Summaries are AI-generated; always consult the original publication for clinical or research decisions.